Single-Nucleus Profiling Reveals a BBB Senescence Unit Driving AD Pathology in Human Brain
Brain study pinpoints how senescent immune cells trigger inflammation in Alzheimer's disease, identifying SPP1 as a testable drug target.
Integration of snRNA-seq data from 75 human brain samples reveals a coordinated multi-cell 'BBB senescence unit' in Alzheimer's disease where senescent microglia upregulate SPP1 and senescent astrocytes overexpress CD44, creating a self-sustaining inflammatory loop that drives AD progression. SPP1 validated as a hub gene in CSF proteomics from AD patients, making it an immediately testable therapeutic target for senolytic or anti-inflammatory interventions.
What the study was
- Study design
- Single-nucleus RNA-seq on human brain samples with CSF proteomics validation
- Population
- Alzheimer's disease patients and controls
- Sample size
- 75
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Molecular Neurobiology
Why it surfaced
Novel 'BBB senescence unit' concept supported by 75-brain snRNA-seq dataset with cross-validated SPP1-CD44 axis — mechanistically actionable for senolytic strategies in AD; Mol Neurobiol indexed; AD has enormous unmet need; CSF proteomics validation adds translational credibility. Alert suppressed this run due to 5-alert cap (6th HIGH article).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.